JAK
JAK (Janus kinase) inhibitors are compounds that target the JAK-STAT signaling pathway, which is involved in cell growth, immune response, and angiogenesis. By inhibiting JAK, these compounds can reduce the signaling that leads to the formation of new blood vessels in tumors, thereby inhibiting tumor growth. JAK inhibitors are important in the treatment of cancers and inflammatory diseases. At CymitQuimica, we offer a diverse range of high-quality JAK inhibitors to support your research in oncology, immunology, and angiogenesis.
Products of "JAK"
Sort by
AMG-47a
CAS:AMG-47a inhibits Lck, T cell growth, and degrades KRAS oncoprotein, affecting EGFP-KRASG12V but not EGFP.Formula:C29H28F3N5O2Purity:98%Color and Shape:SolidMolecular weight:535.56Ruxolitinib
CAS:Ruxolitinib (INCB018424) is a JAK1/2 inhibitor (IC50=3.3/2.8 nM) that is potent and selective.Formula:C17H18N6Purity:100% - 99.99%Color and Shape:SolidMolecular weight:306.36Ref: TM-T1829
5mg58.00€10mg74.00€25mg92.00€50mg116.00€100mg155.00€200mg245.00€500mg414.00€1mL*10mM (DMSO)65.00€SHR0302
CAS:SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3,Formula:C18H22N8O2SPurity:99.11%Color and Shape:SolidMolecular weight:414.48Ref: TM-T9195
1mg160.00€5mg393.00€10mg620.00€25mg1,035.00€50mg1,483.00€100mg1,882.00€1mL*10mM (DMSO)455.00€lirucitinib
CAS:Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.Formula:C16H25N5OSColor and Shape:SolidMolecular weight:335.468JAK-IN-11
CAS:JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.Formula:C23H22FN5O4SPurity:99.57%Color and Shape:SolidMolecular weight:483.52Tofacitinib
CAS:Tofacitinib (Tasocitinib) is an orally Janus kinase inhibitor. Tofacitinib is used for the treatment of rheumatoid arthritis. Cost effective and quality assured.Formula:C16H20N6OPurity:100% - 99.71%Color and Shape:SolidMolecular weight:312.37JAK1/STAT3-IN-1
JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).Formula:C30H33FN4O3SColor and Shape:SolidMolecular weight:548.67AZD-1480
CAS:AZD1480: JAK2 inhibitor, IC50 0.26 nM; selective vs Tyk2, JAK3; less on JAK1. Used in solid tumors, PPV, PMF, ET trials.Formula:C14H14ClFN8Purity:97.5% - 98.55%Color and Shape:SolidMolecular weight:348.77TG101209
CAS:TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.Formula:C26H35N7O2SPurity:100% - 99.36%Color and Shape:SolidMolecular weight:509.67JAK-IN-27
CAS:JAK-IN-27, also known as compound 1, is an orally active, potent inhibitor of the JAKS family kinases, displaying inhibitory concentrations (IC50s) of 3.0 nMFormula:C20H21F2N7OPurity:98%Color and Shape:SolidMolecular weight:413.42JAK2-IN-11
CAS:JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.Formula:C31H31F3N8O4Color and Shape:SolidMolecular weight:639.64Fedratinib
CAS:Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.Formula:C27H36N6O3SPurity:98.23% - 99.96%Color and Shape:SolidMolecular weight:524.68Ref: TM-T1995
1g625.00€5mg49.00€10mg69.00€50mg113.00€100mg134.00€200mg216.00€500mg472.00€1mL*10mM (DMSO)57.00€Pyridone 6
CAS:Pyridone 6, a selective JAK1/2/3 and Tyk2 inhibitor with IC50s: JAK1=15 nM, JAK2=1 nM, JAK3 (Ki=5 nM), Tyk2=1 nM; weakly binds other kinases (130 nM-10 μM).Formula:C18H16FN3OPurity:97.10% - 98.74%Color and Shape:SolidMolecular weight:309.34Ref: TM-T3080
1mg82.00€2mg106.00€5mg162.00€10mg221.00€25mg449.00€50mg658.00€100mg939.00€500mg1,882.00€1mL*10mM (DMSO)177.00€Baricitinib
CAS:Baricitinib (INCB028050) is an orally JAK1 and JAK2 inhibitor. Baricitinib has anti-inflammatory and anti-tumor activity. Cost-effective and quality-assured.Formula:C16H17N7O2SPurity:100% - 99.79%Color and Shape:SolidMolecular weight:371.42Ref: TM-T2485
5mg50.00€10mg73.00€25mg90.00€50mg115.00€100mg144.00€200mg188.00€500mg311.00€1mL*10mM (DMSO)69.00€JAK1-IN-4
CAS:JAK1-IN-4 selectively blocks JAK1 (IC50 = 85 nM) over JAK2/JAK3 and halts STAT3 phosphorylation in NCI-H 1975 cells (IC50 = 227 nM).Formula:C26H32FN9O2Purity:98%Color and Shape:SolidMolecular weight:521.59Filgotinib
CAS:Filgotinib (GLPG0634) is a selective JAK1 inhibitor. The IC50 values against JAK1, JAK2, JAK3, and TYK2 are 10 nM, 28 nM, 810 nM, and 116 nM, respectively.Formula:C21H23N5O3SPurity:98.03% - ≥95%Color and Shape:SolidMolecular weight:425.5JAK2 Inhibitor V
CAS:JAK2 Inhibitor V (JAK2 Inhibitor V Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.Formula:C23H24N2OPurity:96.69% - 99.15%Color and Shape:SolidMolecular weight:344.45Ref: TM-T3042
2mg39.00€5mg57.00€10mg85.00€25mg157.00€50mg274.00€100mg505.00€500mg1,121.00€1mL*10mM (DMSO)63.00€DPP
CAS:DPP, a Platinum(IV) complex with a pterostilbene-derived axial ligand, inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, demonstratingFormula:C36H40Cl2N2O10PtPurity:98%Color and Shape:SolidMolecular weight:926.7AJI-100
CAS:AJI-100 serves as a dual-target inhibitor, effectively blocking Aurora kinase A and JAK2, with respective IC50 values of 12.7 nM and 18.5 nM. It inhibits T cell mitosis and cell polarity by directly targeting Aurora kinase A and reduces STAT3 phosphorylation by inhibiting JAK2 activation, consequently diminishing the differentiation of TH1 and TH17 cells. This compound is utilized in researching immune response regulation and the prevention of graft-versus-host disease (GVHD).Formula:C17H14FN5OColor and Shape:SolidMolecular weight:323.32TCS 21311
CAS:TCS 21311 (NIBR3049) selectively inhibits JAK3 (IC50: 8 nM) and PKCα/θ & GSK3β; >100x selective over JAK1, JAK2, TYK2.Formula:C27H25F3N4O4Purity:≥98%Color and Shape:SolidMolecular weight:526.51Ruxolitinib (S enantiomer)
CAS:Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.Formula:C17H18N6Purity:99.37% - 99.79%Color and Shape:SolidMolecular weight:306.36JAK2-IN-9
CAS:Compound A8, known as JAK2-IN-9, is a selective JAK2 inhibitor with an IC50 of 5 nM.Formula:C20H24N6O2SPurity:98%Color and Shape:SolidMolecular weight:412.514-(3'-HYDROXYPHENYL)AMINO-6,7-DIMETHOXYQUINAZOLINE, HCL
CAS:Formula:C16H16ClN3O3Purity:97.0%Molecular weight:333.7695AG490
CAS:AG490 inhibits EGFR (0.1 μM IC50), 135x > selective than ErbB2, blocks JAK2, spares Lyn, Lck, Syk, Btk, Src.Formula:C17H14N2O3Purity:98.6% - 99.39%Color and Shape:Yellow SolidMolecular weight:294.3BD750
CAS:BD750 is an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation(IC50 of 1.5 μM and 1.1 μM inFormula:C14H13N3OSPurity:99.02%Color and Shape:SolidMolecular weight:271.34WHI-P180 Hydrochloride
CAS:Formula:C16H15N3O3·HClPurity:>97.0%(T)(HPLC)Color and Shape:White to Light gray to Light yellow powder to crystalMolecular weight:333.77Fedratinib hydrochloride hydrate
CAS:Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.Formula:C27H40Cl2N6O4SPurity:98.96% - 99.46%Color and Shape:SolidMolecular weight:615.61JAK-IN-3
CAS:JAK-IN-3 is a potent JAK inhibitor that inhibits JAK3, JAK1, TYK2, and JAK2, and can be used for the study of immune system disorders.Formula:C18H20N4O3Purity:98.04% - 98.19%Color and Shape:SolidMolecular weight:340.38Ref: TM-T11704
1mg133.00€2mg188.00€5mg321.00€10mg518.00€25mg1,035.00€50mg1,644.00€100mg2,680.00€200mg3,591.00€1mL*10mM (DMSO)354.00€Momelotinib Mesylate
CAS:Momelotinib Mesylate is an ATP-competitive JAK1/JAK2 inhibitor (IC50: 11 nM/18 nM). It has 10-fold selectivity versus JAK3.Formula:C24H26N6O5SPurity:98%Color and Shape:SolidMolecular weight:510.57Delgocitinib
CAS:Delgocitinib is a potent JAK inhibitor (IC50: 2.8-58 nM), treats inflammatory diseases, and is the first topical drug for atopic dermatitis.Formula:C16H18N6OPurity:99.90%Color and Shape:SolidMolecular weight:310.35Ref: TM-T15096
1mg169.00€5mg311.00€10mg487.00€25mg929.00€50mg1,415.00€100mg2,062.00€200mg2,775.00€1mL*10mM (DMSO)349.00€CP-352664
CAS:CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.Formula:C18H18N4Color and Shape:SolidMolecular weight:290.36LFM-A13
CAS:LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR,Formula:C11H8Br2N2O2Purity:99.9%Color and Shape:SolidMolecular weight:360JAK1-IN-10
CAS:JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, functions as a potent and selective inhibitor of JAK1 [1].Formula:C15H17N7Purity:98%Color and Shape:SolidMolecular weight:295.34Tyk2-IN-20
CAS:Tyk2-IN-20 (Example 289) is an effective inhibitor of Tyk2 with an IC50 value below 5 nM. Additionally, it inhibits JAK1, JAK2, and JAK3 with IC50 values under 100 nM. This compound is utilized for the research of inflammatory diseases.Formula:C24H25N7O2Color and Shape:SolidMolecular weight:443.50Brepocitinib
CAS:Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).Formula:C18H21F2N7OPurity:99.8%Color and Shape:SolidMolecular weight:389.4Ref: TM-TQ0010
1mg35.00€5mg74.00€10mg110.00€25mg226.00€50mg411.00€100mg660.00€200mg917.00€1mL*10mM (DMSO)81.00€RO8191
CAS:RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.Formula:C14H5F6N5OPurity:98.85% - ≥98%Color and Shape:SolidMolecular weight:373.21MM-589 TFA
CAS:MM-589 TFA is a potent WD repeat domain 5 (WDR5)inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.Formula:C30H45F3N8O7Purity:98%Color and Shape:SolidMolecular weight:686.72Atractylenolide I
CAS:Atractylenolide-I reduces inflammation, improves sepsis, liver, and kidney function, and enhances EOC cell sensitivity to paclitaxel.Formula:C15H18O2Purity:97.55% - 99.83%Color and Shape:SolidMolecular weight:230.3AJI-214
CAS:AJI-214 functions as a dual-target inhibitor that specifically blocks Aurora kinase A and JAK2. By directly inhibiting Aurora kinase A, AJI-214 prevents mitotic progression and cell polarity in T cells while concurrently suppressing JAK2 activation to reduce STAT3 phosphorylation. This inhibition decreases the differentiation of TH1 and TH17 cells. AJI-214 is utilized in research focused on the modulation of immune responses and the prevention of graft-versus-host disease (GVHD).Formula:C17H13ClFN5OColor and Shape:SolidMolecular weight:357.77WDR5-IN-6
CAS:WDR5-IN-6 is a WDR5 inhibitor targeting the WBM locus.WDR5-IN-6 is highly synergistic with OICR-9429, a WDR5 inhibitor that targets the WIN locus.WDR5-IN-6Formula:C13H8Cl2N2O2SPurity:99.69%Color and Shape:SoildMolecular weight:327.19JAK kinase-IN-1
CAS:JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32Formula:C17H19F2N7OSPurity:98%Color and Shape:SolidMolecular weight:407.44ITK inhibitor 2
CAS:ITK inhibitor 2 is a interleukin-2-inducible T-cell kinase (ITK) inhibitor , with an IC50 of 2 nM.Formula:C25H33N5O2Color and Shape:SolidMolecular weight:435.56JAK-IN-31
CAS:JAK-IN-31 (Example 75), a JAK inhibitor, demonstrates IC50 values of ≤0.01 µM for JAK1, ≤0.01 µM for JAK2, 0.01-0.1 µM for JAK3, and ≤0.01 µM for Tyk2,Formula:C21H19N7O2S2Purity:98%Color and Shape:SolidMolecular weight:465.55G5-7
CAS:G5-7 is an oral JAK2 inhibitor targeting EGFR/STAT3 phosphorylation with potential for glioma research.Formula:C22H19F2NO3Purity:97.30%Color and Shape:SolidMolecular weight:383.39Ref: TM-T8742
1mg50.00€5mg97.00€10mg145.00€25mg259.00€50mg374.00€100mg523.00€200mg710.00€1mL*10mM (DMSO)105.00€RO495
CAS:RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assaysFormula:C17H14Cl2N6OPurity:97.94%Color and Shape:SolidMolecular weight:389.24Ref: TM-T22416
1mg64.00€2mg87.00€5mg117.00€10mg183.00€25mg354.00€50mg520.00€100mg702.00€200mg944.00€1mL*10mM (DMSO)140.00€Protosappanin A
CAS:Protosappanin A combats brain inflammation, suppresses rat heart transplant rejection, fights MRSA, and inhibits HIV with a 12.6 uM IC50.Formula:C15H12O5Purity:100% - 99.42%Color and Shape:SolidMolecular weight:272.25Ref: TM-TJS1779
1mg87.00€5mg216.00€10mg354.00€25mg582.00€50mg825.00€100mg1,111.00€1mL*10mM (DMSO)197.00€Momelotinib
CAS:Momelotinib (LM-1149), an oral JAK1/2 inhibitor with IC50s 11/18 nM, blocks ATP binding, disrupting JAK-STAT pathway and reducing tumor growth.Formula:C23H22N6O2Purity:97.47% - 99.56%Color and Shape:SolidMolecular weight:414.46Ref: TM-T1849
1mg38.00€2mg49.00€5mg81.00€10mg95.00€25mg166.00€50mg259.00€100mg406.00€200mg625.00€1mL*10mM (DMSO)88.00€JAK-IN-34
CAS:JAK-IN-34 (compound 11n) is a potent inhibitor of Janus kinases (JAKs), demonstrating IC50 values of 0.40 nM for JAK1, 0.83 nM for JAK2, 2.10 nM for JAK3,Formula:C27H26N6OPurity:98%Color and Shape:SolidMolecular weight:450.53JAK3/BTK-IN-2
CAS:JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor.Formula:C25H32N8O2Purity:99.64%Color and Shape:SolidMolecular weight:476.57
